Objective: The objective of this study was to evaluate effectiveness, retention, and tolerability of brivaracetam (BRV) in genetic generalized epilepsies (GGE) in clinical practice. Methods: A multicenter, retrospective cohort study recruiting all patients that started BRV in 2016 and 2017. Results: A total of 61 patients (mean age = 29.8, range = 9-90 years, 41 female
| INTRODUCTION
Genetic generalized epilepsies (GGE; also called idiopathic generalized epilepsies) are a group of epilepsy syndromes characterized by seizures of generalized onset, such as absence, myoclonic, or primary generalized tonic-clonic seizures (pGTCS) and typical electroencephalographic (EEG) findings such as generalized epileptiform discharges. 1, 2 They account for about 20%-30% of all epilepsies. 3 There is only a limited number of antiepileptic drugs (AEDs) licensed for the treatment of GGE, such as valproate (VPA), ethosuximide, topiramate, lamotrigine (LTG), levetiracetam (LEV), and perampanel (PER). 4, 5 However, AEDs play a central and crucial role in the treatment of these patients, as (1) a substantial number of GGE patients require anticonvulsant treatment for an extended period of time and (2) there is no surgical treatment option for these patients. Furthermore, in contrast to the perceived excellent prognosis, up to 20% of GGE patients remain refractory to AEDs. 6, 7 Overall, patients with drug-refractory epilepsies are affected by increased morbidity and mortality, social stigma, reduced employment opportunities, and impaired quality of life for both themselves and their caregivers. [8] [9] [10] [11] [12] Introduction of a new AED provides an opportunity to achieve better seizure control for some patients. 13, 14 Data on treatment of GGE with newer drugs not yet approved for treatment of GGE, such as lacosamide, zonisamide, and brivaracetam (BRV), remain scarce. BRV is the latest approved AED as add-on therapy for the treatment of partial onset seizures, with or without secondary generalization, in adult and adolescent patients with epilepsy aged ≥16 years. 15 It is a high-affinity synaptic vesicle protein 2A ligand that exceeds the binding potential of LEV by 10-to 30-fold. [15] [16] [17] [18] [19] [20] BRV showed promising results in clinical trials and had low discontinuation rates. 15 Pathophysiological assumptions, efficacy of LEV in idiopathic generalized epilepsy with myoclonic seizures, and available data on use of BRV in patients with absences, myoclonia, and pGTCS are indicative of possible efficacy of BRV in GGE. [21] [22] [23] [24] [25] As study data regarding use of BRV in GGE are scarce, it remains pivotal to assess such new AEDs in terms of their efficacy, tolerability, and retention, a robust factor combining the former two with long-term safety in a real-life setting. Our multicenter study aimed to give insights into the off-label use of BRV in a large cohort of patients with GGE during the first 2 years after market authorization.
| MATERIALS AND METHODS

| Study settings and design
This retrospective study was performed at the epilepsy centers in Berlin, Frankfurt am Main, Greifswald, Kork, Marburg, Münster, and Neuruppin, Germany. The study was not sponsored or funded by any third party and was granted approval by the ethics committee. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines were followed. 26 We reviewed the medical records of all epilepsy patients with GGE treated in 2016 and 2017 for use of BRV. All patients who were exposed to at least one dose of BRV were included. In addition, we report two cases of absence status epilepticus (SE) in which intravenous BRV was used as emergency treatment. The classification of seizure types, epilepsies, SE, and drug resistance was based on the definitions proposed by the International League Against Epilepsy. 1, 2, 27, 28 The treating physician at each study site provided information on epilepsy syndrome, semiology, demographics, concomitant and previous AEDs, with detailed history on use of LEV, comorbidities, including modified Rankin Scale, 29 
| Data entry and statistical analysis
Statistical analyses were performed using IBM SPSS Statistics, version 22.0 (IBM, Armonk, NY, USA). Retention time for BRV was estimated using Kaplan-Meier survival curves, and the log-rank test was performed for comparison between patients switched from LEV and those not taking LEV prior to starting BRV. Chi-square tests were used to compare groups of different clinical characteristics. All P values were two-sided and were regarded as statistically significant at <0.05.
| RESULTS
| Patient characteristics at baseline
A total of 61 GGE patients with a mean age of 29.8 ± 15.8 years (median = 27, range = 9-90 years) started BRV; 41 patients were female (67%), 12 patients (20%) were children or adolescents <18 years old, and two patients (3%) were older than 65 years. In total, 16 (26%) were diagnosed as having juvenile myoclonic epilepsy (Janz syndrome), four (7%) childhood absence epilepsy, three (5%) Jeavons syndrome, two (3%) myoclonic astatic epilepsy, and 36 (59%) other GGE, including patients with GTCS only. The patients had a mean epilepsy duration of 17.7 ± 13.8 years (median = 15, range = 1-71 years), with epilepsy onset at a mean age of 12.1 ± 9.1 years (median = 12, range = 1-52 years). Disability, as measured by modified Rankin Scale, was present in 4 patients (modified Rankin Scale 3-4: 7%). Charlson Comorbidity Index showed no comorbidities in 55 patients (90%), whereas six patients had a score between 1 and 4 (10%), reflecting a low to moderate number of comorbidities. The patients were difficult to control, taking a mean number of 1.9 ± 0.8 AEDs (median = 2, range = 1-4 AEDs) before starting BRV. LEV (n = 31, 51%, mean dose = 2015 mg), LTG (n = 22, 36%, mean dose = 320 mg), VPA (n = 17, 28%, mean dose = 1185 mg), topiramate (n = 10, 16%, mean dose = 265 mg), zonisamide (n = 5, 8%, mean dose = 280 mg), and ethosuximide (n = 3, 5%, mean dose = 863 mg) were the most frequently prescribed drugs before initiation or switch to BRV. None of the patients was taking PER. VPA was used in nine of 20 (45%) male and in eight of 41 (19%; P = 0.037) female patients. In total, 51 patients (84%) were exposed to LEV during their lifetime. In the past, the patients had failed a mean number of 2.4 ± 2.8 AEDs (median = 2, range = 0-14 failed AEDs, current AEDs not included). In total, 55 patients (90%) had a drug-resistant epilepsy according to the International League Against Epilepsy definition. The patients had an overall mean seizure frequency of 22.0 ± 41.5 seizures per month (median = 11, range = 0-300) during the 3-month baseline phase, with three patients being seizure-free for the past 3 months prior to start of BRV. During baseline, a subgroup of 31 patients (51%) suffered from GTCS at a frequency of 5.3 ± 7.6 per month (median = 2, range = 0.1-30). GTCS were present in 41 patients (67%) during their lifetime.
| Treatment with BRV
The initial daily dose of BRV in patients not on LEV (n = 30) varied between 25 mg and 150 mg (mean = 65 ± 29.8 mg, median = 50 mg). The target dose ranged between 25 mg and 200 mg (mean = 134.2 ± 54.3 mg, median = 100 mg) and was achieved within a median time of 7 days.
Patients on LEV were switched to BRV (n = 31) at a median ratio of 15:1 (mean = 18.3:1, range = 7:1 to 40:1). The switch was performed directly overnight from one dose to the next in 26 cases; in five cases, a switch was performed in an overlapping fashion. The initial dose ranged between 50 mg and 300 mg (mean = 131 ± 83.9 mg, median = 100 mg). The target dose ranged between 50 mg and 400 mg (mean = 180 ± 79.4 mg, median = 200 mg). There were no adverse events associated specifically with direct versus overlapping switch from LEV to BRV.
| Retention, responders, and seizure-free patients
The probability of remaining on BRV treatment for all patients was 82.4% at 3 months, 69.2% at 6 months, and 51.5% at 12 months. Discontinuation in 22 patients (36%) was mainly due to insufficient efficacy (n = 12, 20%), adverse events (n = 6, 10%) or both (n = 4, 7%).
who were seizure-free during baseline) were either seizure-free (n = 15, 25%) or reported at least 50% reduction in seizures. No change in seizure frequency was observed in 31 (51%) patients, and 3 (5%) had an increase in seizures. In five (8%) patients, response was not well quantifiable. Details of response according to clinical characteristics are presented in Table 1 . Long-term response of at least 50% seizure reduction was present in 17 patients (28%; 11 seizure-free [18%]) for >6 months and in 14 patients (23%; 10 seizure-free [16%]) for >12 months.
The length of exposure to BRV ranged from 7 days to 24 months, with a mean retention time of 7.9 months (median = 6.5), resulting in a total exposure time to BRV of 483 months. Retention time, defined as the probability of remaining on treatment with BRV, was assessed using Kaplan-Meier survival curves for all patients ( Figure 1A ) and depending on switch from LEV to BRV ( Figure 1B) . Retention did not differ between patients started on BRV or switched from LEV (log-rank P = 0.88). The daily dose of BRV at last follow-up varied between 25 mg and 400 mg (mean = 173.5 ± 82.3 mg, median = 200 mg), with eight patients taking a daily dose exceeding 200 mg.
| TEAEs
TEAEs were reported in 16 (26%) patients, 10 (16%) patients reported central nervous system-related TEAEs, Seizure types refer to overall occurrence of different seizure types during lifetime, including GTCS, myoclonic seizures, and absence seizures. The category "All seizure types" includes patients who suffered from GTCS, myoclonic, and absence seizures. and nine (15%) patients reported psychobehavioral TEAEs. We did not observe any dose dependence of TEAEs. All reported TEASs are listed in Table 2 . Psychobehavioral TEAEs occurred in five of 30 (17%) patients who had previously reported psychobehavioral TEAEs on LEV and in four of 31 (13%) patients who did not experience psychobehavioral TEAEs on LEV or were not exposed to LEV (not significant).
| Intravenous BRV for acute treatment of absence SE
Two female patients of childbearing age with GGE had absence SE as proven by continuous EEG recording. In both cases, treatment with VPA was avoided in the first place.
The 28-year-old patient presented to the emergency room with decreased responsiveness for a few hours. Continuous 3-Hz spike-and-wave complexes were present on EEG. She was treated with bolus doses of lorazepam up to 4 mg and BRV up to 300 mg within 20 minutes. As the absence SE did not cease after a further 15 minutes, VPA 1600 mg and lacosamide 400 mg were applied, leading to cessation of SE activity on EEG.
The 22-year-old patient suffered from absence SE during video-EEG monitoring with recording of generalized 3-Hz spike-and-wave complexes accompanied by decreased responsiveness. She received 10 mg of intranasal midazolam 32 followed by a bolus of 200 mg BRV. As SE did not cease within 30 minutes, VPA 1000 mg and lorazepam 2 mg were applied, stopping SE.
| DISCUSSION
Our study reflects the experience during the first 2 years after market access of BRV in a cohort of 61 patients with GGE according to an off-label use. Our patients represent a difficult to control group as they failed a mean number of 2.4 AEDs in the past and were taking a mean number of 1.9 AEDs before starting BRV. A substantial proportion, 18% and 16%, of patients could achieve long-term seizure freedom for more than 6 or 12 months. Effectiveness with 36% being either seizure-free (25%) or reporting a 50% seizure reduction for 3 months and 28% | 1553 being either seizure-free (18%) or reporting a 50% seizure reduction for 6 months is in line with what was observed during randomized, double-blind controlled trials in focal epilepsies. 33 This is somewhat surprising, considering that most patients were currently being or had been treated with LEV (84%) and that previous LEV exposure was reported to be associated with lower responder rates. 33 In clinical practice, uptitration of newly added AEDs is common practice, and we dosed BRV to a mean of 173.5 mg (median = 200 mg), with eight patients taking a daily dose exceeding 200 mg. Therefore, BRV underdosing in our study is unlikely. Efficacy and retention did not differ between patients switched from LEV as compared to patients not currently taking LEV. Table 1 summarizes possible clinical predictors for response; however, extended statistical analysis is precluded by the limited number of GGE patients. Nevertheless, our study presents the largest published cohort of GGE patients treated with BRV. Patients with juvenile myoclonic epilepsy and female patients show a trend toward a better response rate, the latter possibly caused by active avoidance of VPA in females of childbearing age. The offlabel use of BRV in GGE was influenced by the decreasing use of VPA in females of childbearing age 37 and PER being not available on the German market due to reimbursement issues during the study period (years 2016 and 2017). BRV was relatively well tolerated, with a low rate of TEAEs of 26% in our study. Discontinuation due to adverse events occurred in six patients (10%) and due to adverse events and lack of efficacy in a further four patients (7%). The most frequent TEAEs were somnolence, ataxia, and psychobehavioral TEAEs, as observed in the randomized, double-blind controlled trials. 15, 23, [34] [35] [36] As all patients were followed by specialist epilepsy services, it is unlikely that major or important adverse events were missed. However, as we have a retrospective design, we cannot exclude the possibility of underdetection of TEAEs. Furthermore, due to the absence of central EEG review, patients with frontal lobe seizures resembling GGE with GTCS might have been included. Psychobehavioral TEAEs were closely followed up, and we analyzed the occurrence depending on psychobehavioral TEAEs during previous LEV treatment. In patients who experienced psychobehavioral adverse events while on LEV, starting BRV resulted in psychobehavioral TEASs in five of 30 (17%) patients, whereas this was the case in only four of 31 (13%) patients who did not develop psychobehavioral TEAEs while on LEV or were not exposed to LEV at all. The lower incidence and amelioration of psychobehavioral TEAEs due to switching from LEV to BRV have been shown in one open-label, prospective, exploratory study 31 and postmarketing publications. [38] [39] [40] The latter
showed that the likelihood of psychobehavioral TEAEs was significantly increased in patients who had developed psychobehavioral TEAEs on LEV in the past. 39 Retention rates of 82.4% at 3 months and 69.2% at 6 months are comparable with other AEDs licensed for focal epilepsies in the past decade, such as lacosamide (80% at 6 months, 62%-68% at 1 year), 41, 42 zonisamide (62% at 1 year), 43 PER (60% at 6 months), 44 and eslicarbazepine acetate (80%-82% at 6 months, 72% at 1 year). 45 Postmarketing studies of BRV in predominantly focal epilepsies showed comparable retention rates of 51.5%, 72%, and 75.8% at 6 months. [38] [39] [40] In GGE, sufficient data on retention rates are available for LTG, VPA, and LEV; with the highest retention rates for VPA in all GGE subsyndromes (90% at 3 years), followed by LEV (65% at 3 years; only juvenile myoclonic epilepsy) and LTG (45% at 3 years). 46, 47 Different factors point to BRV's potential as an alternative compound for treatment of SE. BRV is available as an intravenous solution and licensed for bolus injection. BRV rapidly achieves maximal brain concentration within minutes. 48 A noticeable reduction in the cumulative duration of seizures was shown in the rat model of self-sustained SE induced by perforant path stimulation. 49 On the contrary, there is a paucity of reports on the use of BRV in SE with, so far, one report of 11 cases of SE due to a structural etiology. 50 We report the first two cases of BRV in absence SE, where VPA, as a first-line treatment, was avoided in females with childbearing potential. Bolus injections of 200-300 mg of BRV were well tolerated; however, 3-to 4-Hz EEG activity did not cease upon treatment with BRV, and further drugs were administered to terminate SE. Further experience with BRV in SE is still required to warrant recommendation of its use in this emergency situation.
| CONCLUSIONS
We conclude that high seizure-free rates can be achieved using BRV for GGE in clinical practice, even in a cohort wherein 84% of patients had been previously exposed to LEV. Furthermore, BRV appears to be a useful option for patients experiencing psychobehavioral TEAEs associated with LEV, and immediate switching appears feasible.
